Of note, significant adverse effects (any-grade) included peripheral neuropathy (68.2%), cytopenias (50.5% leukopenia and 42.1% leukopenia), alopecia (40.2%), and elevated transaminases (AST 42.1%, ALT 35.5%). This evidence concerns the gene GPT and peripheral neuropathy.